Business
Notice of Allowance of NXP002 Patent in Japan
Notice of Allowance of NXP002 Patent in Japan.
About this update from Nuformix Plc
[{"type":"text","content":"\n\n23 October 2023\n \nNuformix plc\n \n(\"Nuformix\" or the \"Company\")\n \nNotice of Allowance of NXP002 Patent in Japan\n \nNuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has been issued with an Official Decision to Grant Notice of Allowance for Japanese National Phase Patent Application No. 2020-555115 entitled \"CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE\".\n \nNXP002 is the Company's lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (\"IPF\"). The granted patent describes a proprietary new form of the drug tranilast, uniquely enabling delivery via an inhaled nebulised formulation. Nuformix owns two patent applications relating to crystalline forms of tranilast, one of which had already been granted globally. This second patent application, which as has already been granted in the US, specifically addresses the novel tranilast forms being progressed by the Company as a potential novel IPF treatment.\n \nDr Dan Gooding, Executive Director of Nuformix, said: \"I'm delighted we have received this Official Decision to Grant from the Japanese Patent Office. This provides confirmation that no prior art exists in relation to NXP002, which is very important given that this is the territory in which tranilast was first invented and where the vast majority of considerable subsequent development work has been conducted. The grant is therefore an important step forward for our lead asset NXP002. We expect the European grant to follow shortly, which will further support the Company's on-going partnering activities.\"\n \nEnquiries:\n \n\n\n\n\nNuformix plc\n\n\n \n\n\n\n\nDr Dan Gooding, Executive Director\n \n\n\nVia IFC Advisory\n \n\n\n\n\nStanford Capital Partners Limited\n\n\n \n\n\n\n\nTom Price / Patrick Claridge (Corporate Finance)\n\n\n+44 (0) 20 3650 3650\n\n\n\n\nJohn Howes (Corporate Broking)\n\n\n+44 (0) 20 3650 3652\n \n\n\n\n\nIFC Advisory Limited\n\n\n \n\n\n\n\nTim Metcalfe\nZach Cohen\n\n\n+44 (0) 20 3934 6630\[email protected]\n\n\n\n\n \nAbout Nuformix\n \nNuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and ...